Browse > Article

Pharmacogenomics in Drug Discovery and Development  

Ahn, Chul (Department of Medicine, University of Texas Medical School)
Publication Information
Genomics & Informatics / v.5, no.2, 2007 , pp. 41-45 More about this Journal
Abstract
Pharmacogenomics is the study that examines how genetic variations affect the ways in which people respond to drugs. The ways people respond to drugs are complex traits that are influenced by many different genes. Pharmacogenomics intends to develop rational means of optimizing drug therapy, with respect to the patients' genotype, to maximize efficacy with minimal adverse drug reactions. Pharmacogenomics has the potential to revolutionize the practice of medicine, and promises to usher in an area of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Indeed, pharmacogenomics is exploited as an essential step for target discovery and drug development in the pharmaceutical industry. The goal of the personalized medicine is to get the right dose of the right drug to the right patient at the right time. In this article, we will review the use of pharmacogenomics in drug discovery and development.
Keywords
targeted therapy; theragnostics;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ahn, C. and Kang, S.H. Optimal biological dose for molecularly targeted therapies. Encyclopedia of Clinical Trials. In press
2 Cobleigh, M., Langmuir, V., Sledge, G., et al. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminar. Oncol. 30, 117-124   DOI   ScienceOn
3 Frank, R.G. (2003). Editorial: New estimates of drug development costs. Journal of Health Economics 22, 325-330   DOI   ScienceOn
4 Ginsburg, G.S. and Angrist, M. (2006). The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society's report on personalized medicine. Personalized Med. 3, 119-123   DOI   ScienceOn
5 Kuhlmann, J. (2006). The applications of biomarkers in early clinical drug development to improve decision-making processes. Appropriate Dose Selection: How to Optimize Clinical Drug Development. Venitz and Sittner (ed).pp. 29-46
6 Lazarou, J., Pomeranz, B.H., and Corey, P.N. (1998). Incidence of adverse drug reactions in hospitalized patients. J. Amer. Med. Assn. 279, 1200-1205   DOI   ScienceOn
7 Personalized Medicine Coalition. (2006). The case for personalized medicine. New York, NY
8 Roden, D,M., Altman, R,B., Benowitz, N.L., et al. (2006). Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine 145, 749-757   DOI   ScienceOn
9 Sconce, E., Khan, T. Wynne, H., Avery, P. Monkhouse, L., King, B., Wood, P., Kesteven, P., Daly, A., and Kamali, F. (2005).The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333   DOI   ScienceOn
10 Tamura, K. and Fukuoka, M. (2005). Gefitinib in non-small cell lung cancer. Expert Opin. Pharmacother. 6, 985-993   DOI   ScienceOn
11 Womack, C. (2005). As part of retrofitting, FDA panel votes to relabel warfarin for PGx; Is Dx far behind? Pharmacogenomics Reporter, December
12 Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., et al. (2003). Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology 21, 60-65   DOI   ScienceOn
13 Innocenti, F., Undevia, S.D., and Iyer, L., et al. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of Clinical Oncology 22,1382-1388   DOI   ScienceOn
14 Mancinelli, L., Cronin, M., and Sadée, W. (2000). Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci. 2, 1-13
15 Ozdemir, V., Williams-Jones, B., Cooper, D.M., Someya, T., and Godard, B. (2007). Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 8, 177-185   DOI   ScienceOn
16 DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, 151-185   DOI   ScienceOn
17 Williams-Jones, B. and Corrigan, O.P. (2003). Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am. J. Pharmacogenomics 3, 375-383   DOI   ScienceOn
18 Weinshilboum, R.M. and Wang, L. (2006). Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annu. Rev. Genom. Human Genet. 7, 223-245   DOI   ScienceOn
19 Phillips, K.A., Veenstra, D.L., Oren, E., Lee, K., and Sadée, W. (2001). The potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. J. Amer. Med. Assn. 286, 2270-2279   DOI   ScienceOn
20 Ozdemir, V., Williams-Jones, B., Glatt, S.J., Tsuang, M.T., Lohr, J.B., and Reist, C. (2006). Shifting emphasis from pharmacogenomics to theragnostics. Nature Biotechnology 8, 942-946
21 Ratain, M.J. (2007). Personalized Medicine: Building the GPS to take us there. Clinical Pharmacology & Therapeutics 81, 321-322   DOI   ScienceOn
22 FDA. (2004). Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. The Food and Drug Administration. http://www.fda.gov/oc/ initiatives/ criticalpath/whitepaper.pdf
23 Jain, K.K. (2006). Challenges of drug discovery for personalized medicine. Current Opinion in Molecular Therapeutics 8, 487-492